- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07556679
PLAY2CONTROL Study
August 26, 2026 updated by: Patricia Gomez, University of Miami
Active Video Games and Their Effect on Weight Loss and HgbA1c in Patients With Obesity and Type 2 Diabetes Mellitus
The purpose of this study is to assess the impact of active video gaming participation in otherwise sedentary patients with obesity and Type 2 diabetes mellitus.
The study will assess changes in sedentary time, activity level and changes in weight and Hemoglobin A1c, as well as other complications related to obesity that is monitored in clinic.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jessica Landau, D.O.
- Phone Number: 305-243-2920
- Email: jessica.landau@jhsmiami.org
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami
-
Contact:
- Jessica Landau, D.O.
- Phone Number: 305-243-2920
- Email: jessica.landau@jhsmiami.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients followed at the University of Miami Pediatric Endocrinology Clinic
- Must have a diagnosis of Obesity (BMI >= 95th percentile) and Type 2 Diabetes Mellitus (Hemoglobin A1c > 6.5%)
- Children and teenagers, 5-18 years old
- Young adults 19-21 years old
Exclusion Criteria:
- Patients who have conditions preventing physical activity (such as physical limitations)
- Patients without Televisions at home
- Pregnant females
- Patients in juvenile detention or prison
- Adults unable to consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Nex Playground Activity Program
Participants assigned to this arm will receive a Nex Playground gaming console.
Over a 12-month period, participants will be asked to use the gaming system several times per week, with each play session lasting no less than 20 minutes.
Participants will scan the provided activity-tracking QR code during each play session to document gaming system use.
|
Participants are provided with a Nex Playground gaming console and asked to use it regularly at home for no less than 20 minutes at a time, unless otherwise doing another physical activity or sport for this timeframe.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent Weight Change
Time Frame: Baseline to 12 months
|
Percent change in body weight (percentage points) from baseline, measured using clinic calibrated scales during routine visits
|
Baseline to 12 months
|
|
Change in HbA1c
Time Frame: Baseline to 12 months
|
Absolute change in HbA1c (percentage points) from baseline, measured through standard laboratory blood tests performed during routine clinic visits
|
Baseline to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Lipids Levels
Time Frame: Baseline to 12 months
|
Change in lipids levels (milligrams per deciliter) from baseline, measured through fasting lipid panels obtained during routine clinic blood work
|
Baseline to 12 months
|
|
Change in Liver Enzymes
Time Frame: Baseline to 12 months
|
Change in liver enzymes (units per liter) measured through standard liver function tests obtained during routine clinic blood work
|
Baseline to 12 months
|
|
Change in Oral Diabetes Medication Dose
Time Frame: Baseline to 12 months
|
Change in doses of oral antihyperglycemic medications (milligrams), as recorded in the medical record and summarized using the prescribed daily or weekly doses.
|
Baseline to 12 months
|
|
Change in Insulin Dose
Time Frame: Baseline to 12 months
|
Change in insulin dose (units), as recorded in the medical record and summarized as the total prescribed daily insulin units
|
Baseline to 12 months
|
|
Change in Sedentary Time
Time Frame: Baseline to 12 months
|
Absolute change in daily sedentary time (hours), assessed via a clinic-administered sedentary behavior questionnaire.
Sedentary time will be reported as total hours per day.
|
Baseline to 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Patricia Gomez, M.D., University of Miami
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
October 1, 2026
Primary Completion (Estimated)
October 1, 2027
Study Completion (Estimated)
October 1, 2027
Study Registration Dates
First Submitted
April 22, 2026
First Submitted That Met QC Criteria
April 22, 2026
First Posted (Actual)
April 29, 2026
Study Record Updates
Last Update Posted (Actual)
August 27, 2026
Last Update Submitted That Met QC Criteria
August 26, 2026
Last Verified
August 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20260243
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.